Volume of fluid infused · adults or children requiring fluid delivered by a parenteral route (one study testing insertion and the volume of fluid delivered in…
1 finding from 1 review
Insertion failures · adults or children requiring parenteral access for infusion of fluids or medication
Intravenous probably leads to higher insertion failures compared with subcutaneous route (moderate certainty).
1 finding from 1 review
Time to infusion/placement · adults or children requiring parenteral access for infusion of fluids or medication
1 finding from 1 review
Dislodgement of device · adults or children requiring parenteral access for infusion of fluids or medication
Intravenous may leads to higher dislodgement of device compared with subcutaneous route (low certainty).
1 finding from 1 review
Needlestick injuries · adults or children requiring parenteral access for infusion of fluids or medication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Haemoglobin (g/dL) · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Overall quality of life measured at the end of · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Serum ferritin (ng/mL) · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Bacterial infection · non‐anaemic, iron‐deficient adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Peak oxygen consumption taken at the end of · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Serious adverse events · non‐anaemic, iron‐deficient adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events mild adverse events · non‐anaemic, iron‐deficient adults
It is very uncertain whether intravenous iron changes mild adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Side effects or other adverse events · emergency department procedural sedation
1 finding from 1 review
Participant satisfaction (as defined by study authors) · emergency department procedural sedation
1 finding from 1 review
Adverse effects: pain on injection (solution deposition), Heft-Parker VAS 0-170 mm · emergency department procedural sedation
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
It is very uncertain whether intravenous ketorolac changes number of participants with at least 50% pain relief over 4 hours compared with placebo (very low certainty).
1 finding from 1 review